ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Prognostic value of the HALP score in patients with testicular cancer: a retrospective study.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a novel immune nutritional index associated with the prognosis of various malignancies. This study aimed to evaluate the clinical relevance of the HALP score in predicting recurrence, metastasis, and survival outcomes in patients with testicular cancer.
methodsThis retrospective study included 131 patients with histologically confirmed testicular cancer who were treated between January 2010 and December 2024. HALP scores were calculated using the baseline laboratory parameters. An optimal cutoff value of 304.56 was identified using receiver operating characteristic (ROC) curve analysis (AUC: 0.820; 95% CI 0.708-0.902; p < 0.001). Patients were stratified into high and low HALP groups based on this threshold value. Survival outcomes were evaluated using Kaplan-Meier, and Cox proportional hazards regression analyses.
resultsThe median HALP score was 531.1 (IQR: 348.8-728.5). A low HALP score (≤ 304.56) was significantly associated with poorer 1-year overall survival (54.5% vs. 98.2%, p < 0.001) and a 15.6-fold increased risk of death (HR 15.604, 95% CI 2.718-89.645, p = 0.001) based on Cox regression analysis. In the multivariate analysis, a low HALP score (HR: 7.684, p = 0.016), the presence of comorbidity (HR 13.528, p = 0.002), and tunica albuginea invasion (HR 7.255, p = 0.030) were identified as independent predictors of recurrence or metastasis. In addition, the HALP score was significantly associated with disease stage (p < 0.001), with lower scores more commonly observed in patients with advanced-stage disease.
conclusionsThe HALP score was a simple, inexpensive, and effective prognostic biomarker in testicular cancer. A score ≤ 304.56 is independently associated with a higher risk of recurrence, metastasis, and mortality. Incorporating HALP into routine assessments may improve risk stratification and clinical decision-making in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.